Potential benefit with longer therapy for elderly patients with acute myeloid leukemia (AML) kept hope alive for them as well as Cyclacel Pharmaceuticals Inc., which heard from the data safety and monitoring board (DSMB) that the phase III study known as Seamless with lead candidate sapacitabine has crossed the futility boundary and is unlikely to reach a statistically significant level of survival.